These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25061430)

  • 61. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
    Nuijten M; Mittendorf T
    Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical, Radiological and Electrophysiological Comparison of Immunomodulatory Therapies in Multiple Sclerosis.
    Genç G; Demirkaya Ş; Bek S; Odabaşi Z
    Noro Psikiyatr Ars; 2017 Jun; 54(2):116-124. PubMed ID: 28680308
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study.
    Zecca C; Disanto G; Mühl S; Gobbi C
    BMC Neurol; 2017 Sep; 17(1):171. PubMed ID: 28870152
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.
    Hupperts R; Becker V; Friedrich J; Gobbi C; Salgado AV; Sperling B; You X
    Expert Opin Drug Deliv; 2015 Jan; 12(1):15-25. PubMed ID: 25430947
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Interferons in the Treatment of Multiple Sclerosis: A Clinical Efficacy, Safety, and Tolerability Update.
    Filipi M; Jack S
    Int J MS Care; 2020; 22(4):165-172. PubMed ID: 32863784
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
    Bermel RA; You X; Foulds P; Hyde R; Simon JH; Fisher E; Rudick RA
    Ann Neurol; 2013 Jan; 73(1):95-103. PubMed ID: 23378325
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Relationship between disease-modifying therapy and depression in multiple sclerosis.
    Kirzinger SS; Jones J; Siegwald A; Crush AB
    Int J MS Care; 2013; 15(3):107-12. PubMed ID: 24453772
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
    Vermersch P; Czlonkowska A; Grimaldi LM; Confavreux C; Comi G; Kappos L; Olsson TP; Benamor M; Bauer D; Truffinet P; Church M; Miller AE; Wolinsky JS; Freedman MS; O'Connor P;
    Mult Scler; 2014 May; 20(6):705-16. PubMed ID: 24126064
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis.
    Bozkaya D; Livingston T; Migliaccio-Walle K; Odom T
    J Med Econ; 2017 Mar; 20(3):297-302. PubMed ID: 27822961
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
    Drulovic J; Cukic M; Grgic S; Dincic E; Raicevic R; Nadj C; Toncev G; Vojinovic S; Mesaros S; Kisic Tepavcevic D; Dujmovic I; Tadic D; Miletic-Drakulic S; Dackovic J; Kostic S; Erakovic J; Sakalas L; Savic D; Suknjaja V; Martinovic V; Maric G; Pekmezovic T
    Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program.
    Katsarava Z; Ehlken B; Limmroth V; Taipale K; Patel SN; Niemczyk G; Rehberg-Weber K; Wernsdörfer C;
    BMC Neurol; 2015 Sep; 15():170. PubMed ID: 26395989
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.
    Link J; Ramanujam R; Auer M; Ryner M; Hässler S; Bachelet D; Mbogning C; Warnke C; Buck D; Hyldgaard Jensen PE; Sievers C; Ingenhoven K; Fissolo N; Lindberg R; Grummel V; Donnellan N; Comabella M; Montalban X; Kieseier B; Soelberg Sørensen P; Hartung HP; Derfuss T; Lawton A; Sikkema D; Pallardy M; Hemmer B; Deisenhammer F; Broët P; Dönnes P; Davidson J; Fogdell-Hahn A;
    PLoS One; 2017; 12(2):e0170395. PubMed ID: 28170401
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey.
    Haase R; Kullmann JS; Ziemssen T
    Ther Adv Neurol Disord; 2016 Jul; 9(4):250-63. PubMed ID: 27366231
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS.
    Pavelek Z; Sobíšek L; Šarláková J; Potužník P; Peterka M; Štětkárová I; Štourač P; Mareš J; Hradílek P; Ampapa R; Grünermelová M; Vachová M; Recmanová E; Angelucci F; Halúsková S; Vališ M
    Front Neurol; 2020; 11():593527. PubMed ID: 33510704
    [No Abstract]   [Full Text] [Related]  

  • 79. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
    Calabrese M; Bernardi V; Atzori M; Mattisi I; Favaretto A; Rinaldi F; Perini P; Gallo P
    Mult Scler; 2012 Apr; 18(4):418-24. PubMed ID: 21228025
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.